You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Letters Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Karen H. Costenbader; Roberta Glass; Jing Cui; Nancy Shadick
JAMA 2006; 296: 2201.
[Extract][Full text][PDF]
Letters Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Peter E. Callegari; Thomas F. Schaible; Jerome A. Boscia
JAMA 2006; 296: 2202.
[Extract][Full text][PDF]
Letters Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis—Reply
Tim Bongartz; Eric L. Matteson; Victor M. Montori; Alex J. Sutton; Michael Sweeting; Iain Buchan
JAMA 2006; 296: 2203-a-2204-a.
[Extract][Full text][PDF]
Letters Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Original Contributions Effect of Constraint-Induced Movement Therapy on Upper Extremity Function 3 to 9 Months After Stroke: The EXCITE Randomized Clinical Trial
Steven L. Wolf; Carolee J. Winstein; J. Philip Miller; Edward Taub; Gitendra Uswatte; David Morris; Carol Giuliani; Kathye E. Light; Deborah Nichols-Larsen; for the EXCITE Investigators
JAMA 2006; 296: 2095-2104.
[Abstract][Full text][PDF]
Medical News & Perspectives Targeted Cancer Therapies Lagging: Better Trial Design Could Boost Success Rate
